Research summary ·
Ivabradine in the Treatment of POTS Before and After COVID-19 Pandemic: A Systematic Review and Meta-Analysis.
Written based on 1 research study on PubMed, searched on 3 Nov 2026.
What was studied
This review pooled results from past research on the drug ivabradine in POTS. In POTS, the heart races too much when a person stands up. The team searched PubMed, Embase and the Cochrane Library up to August 2025. The review could take in trials, studies that watched people, and case series. They found 9 studies with 245 people in total. They looked mainly at heart rate when standing and lying down.
What they found
Ivabradine lowered heart rate when standing by 18.5 beats each minute. Heart rate lying down fell by 9.7 beats each minute. Papers kept reporting fewer symptoms, such as a pounding heart and feeling faint. Trouble with exercise also seemed to get better. This held in children, after COVID-19, and in other POTS types. Side effects were rare and mild. The most common was short-lived trouble with vision. No paper reported a very slow heart rate or very low blood pressure.
What it means for patients
The authors say ivabradine seems to lower heart rate in POTS. It also seemed to ease symptoms in a real way. Its safety looked good in this research.
Why it is not certain yet
The studies were small and differed a lot from each other. Most of them only watched people, without a split by chance. Results varied most in the children and post-COVID-19 groups. The authors say large trials at many centers are still needed. A review can only be as good as the studies in it.
Source
Ivabradine in the Treatment of POTS Before and After COVID-19 Pandemic: A Systematic Review and Meta-Analysis.
PubMed · PMID 42411507We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Postural tachycardia syndrome (POTS) publications